Skip to content
CNS Clinical Research

New Haven, Connecticut

CNS clinical trials in New Haven, CT

41 CNS studies are recruiting participants at sites in New Haven as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.

Call (888) 520-7418
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

New Haven at a glance

  • 41 studies are recruiting at a site in New Haven.
  • By phase: Early Phase 1 (4), Phase 1 (5), Phase 2 (10), Phase 2/3 (1), Phase 3 (12), No phase (5), Observational (4). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (21), university, hospital or other (19), government (1).
  • By research area: Depression (13), Parkinson's Disease (13), Epilepsy (5), Bipolar Disorder (3), Schizophrenia (3), Migraine (2), Multiple Sclerosis (2).
  • Most recent update to one of these records: November 16, 2026.

Depression studies recruiting in New Haven

Basic details from each study's public record (the 30 most recently updated of 41). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Open-Label Psilocybin Study in Transdiagnostic Population

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Yale University
    Study site
    Connecticut Mental Health Center - Yale School of Medicine
    Registry record
    NCT06442423 · updated
  2. A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 85
    • All sexes
    Sponsor
    Cybin IRL Limited
    Study site
    Yale School of Medicine - Yale Program for Psychedelic Science
    Registry record
    NCT06793397 · updated
  3. A Study of Brenipatide in Adult Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Yale University School of Medicine
    Registry record
    NCT07412756 · updated
  4. A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Yale Child Study Center
    Registry record
    NCT07227454 · updated
  5. A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT07196501 · updated
  6. The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

    • Phase 2
    • Ages 40 to 80
    • All sexes
    Sponsor
    Yale University
    Study site
    Yale University
    Registry record
    NCT07610369 · updated
  7. PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Yale University
    Study site
    Yale School of Medicine
    Registry record
    NCT06713616 · updated
  8. The OBSERVE Protocol

    • Observational
    • All ages
    • All sexes
    Sponsor
    Yale University
    Study site
    Yale School of Medicine
    Registry record
    NCT06725277 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in New Haven, CT on ClinicalTrials.gov.

Schizophrenia studies recruiting in New Haven

  1. A Study of Brenipatide in Adult Participants With Schizophrenia

    • Phase 2
    • Ages 18 to 55
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Yale University School of Medicine
    Registry record
    NCT07410507 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in New Haven, CT on ClinicalTrials.gov.

Bipolar disorder studies recruiting in New Haven

  1. A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Yale University School of Medicine
    Registry record
    NCT07286175 · updated
  2. A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Yale New Haven Hospital-Smilow Cancer Center
    Registry record
    NCT06929273 · updated
  3. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Connecticut Mental Health Center
    Registry record
    NCT06951698 · updated

Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in New Haven, CT on ClinicalTrials.gov.

Parkinson's disease studies recruiting in New Haven

  1. A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Yale University School of Medicine ( Site 6009)
    Registry record
    NCT06952504 · updated
  2. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Yale University School of Medicine ( Site 0201)
    Registry record
    NCT06623422 · updated
  3. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    • Phase 3
    • Ages 50 to 85
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Institute for Neurodegenerative Disorders
    Registry record
    NCT07174310 · updated
  4. A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

    • Phase 2/3
    • Ages 40 to 80
    • All sexes
    Sponsor
    Biohaven Therapeutics Ltd.
    Registry record
    NCT06976268 · updated
  5. MK-0947 PN-002: An Open-label Study to Evaluate Brain α-synuclein Deposition Using Positron Emission Tomography (PET) and [¹⁸F]MK-0947 in Participants With Parkinson's Disease (PD)

    • Phase 1
    • Ages 40 to 80
    • All sexes
    Sponsor
    XingImaging, LLC
    Study site
    XingImaging, LLC
    Registry record
    NCT07880379 · updated
  6. This Protocol is a Sub-study Under the PPMI Program. It is a Longitudinal, Single-center Study to Assess the Performance of [18F]AV-133 Imaging Using High and Standard Resolution PET in Individuals Enrolled With Parkinson's Disease (PD) for up to 12 Months.

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Michael J. Fox Foundation for Parkinson's Research
    Study site
    Institute for Neurodegenerative Disorders
    Registry record
    NCT07830654 · updated
  7. A Comparative Performance Study Between High and Standard Resolution Positron Emission Tomography Camera Using [18F] AV-133 in Prodromal Parkinson's Disease

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Michael J. Fox Foundation for Parkinson's Research
    Study site
    Institute for Neurodegenerative Disorders
    Registry record
    NCT07809438 · updated
  8. Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease

    • Phase 2
    • Ages 45 to 85
    • All sexes
    Sponsor
    Michael J. Fox Foundation for Parkinson's Research
    Study site
    Institute for Neurodegenerative Disorders / XingImaging, LLC
    Registry record
    NCT07020026 · updated
  9. PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

    • Observational
    • Ages 30 and older
    • All sexes
    Sponsor
    Michael J. Fox Foundation for Parkinson's Research
    Study site
    Institute For Neurodegenerative Disorders
    Registry record
    NCT04477785 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in New Haven, CT on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in New Haven

  1. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Smilow Cancer Center/Yale-New Haven Hospital · Yale University
    Registry record
    NCT03816345 · updated
  2. Exploring the Utility of [18F]3F4AP for Demyelination Imaging

    • Phase 1
    • Ages 18 to 90
    • All sexes
    Sponsor
    Yale University
    Study site
    Yale University PET Center
    Registry record
    NCT06999434 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in New Haven, CT on ClinicalTrials.gov.

Epilepsy studies recruiting in New Haven

  1. A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

    • Phase 3
    • Ages 2 and older
    • All sexes
    Sponsor
    Epygenix
    Study site
    Yale School of Medicine - Yale-New Haven Hospital
    Registry record
    NCT04462770 · updated
  2. Diagnosing Epilepsy To EffeCT Change

    • No phase
    • Ages 18 to 75
    • All sexes
    Sponsor
    Epiminder America, Inc.
    Study site
    Yale School of Medicine
    Registry record
    NCT07110337 · updated
  3. Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up

    • Observational
    • Ages 18 to 75
    • All sexes
    Sponsor
    Epiminder America, Inc.
    Study site
    Yale School of Medicine
    Registry record
    NCT07110454 · updated
  4. RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Study site
    Yale University
    Registry record
    NCT06798896 · updated
  5. Subcortical Arousal in Perceptual Awareness

    • No phase
    • Ages 13 and older
    • All sexes
    Sponsor
    Yale University
    Study site
    Yale School of Medicine
    Registry record
    NCT06934356 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in New Haven, CT on ClinicalTrials.gov.

Migraine studies recruiting in New Haven

  1. Study of EVO756 in Adults With Migraine

    • Phase 2
    • Ages 18 to 64
    • All sexes
    Sponsor
    Evommune, Inc.
    Study site
    Hasbani Neurology
    Registry record
    NCT07616128 · updated
  2. A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    H. Lundbeck A/S
    Study site
    Yale School of Medicine - The Scirex Clinical Research Unit
    Registry record
    NCT05164172 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in New Haven, CT on ClinicalTrials.gov.

Ask about studies near New Haven

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 520-7418

or send a short form

How should we reach you?

Call